Compare Fulford India with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FULFORD INDIA vs GLENMARK PHARMA - Comparison Results

FULFORD INDIA     Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FULFORD INDIA GLENMARK PHARMA FULFORD INDIA/
GLENMARK PHARMA
 
P/E (TTM) x 398.8 11.4 3,503.8% View Chart
P/BV x 6.2 1.6 382.0% View Chart
Dividend Yield % 0.1 0.6 13.7%  

Financials

 FULFORD INDIA   GLENMARK PHARMA
EQUITY SHARE DATA
    FULFORD INDIA
Mar-14
GLENMARK PHARMA
Mar-19
FULFORD INDIA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs942712 132.4%   
Low Rs450484 93.1%   
Sales per share (Unadj.) Rs691.4349.6 197.7%  
Earnings per share (Unadj.) Rs11.532.8 35.0%  
Cash flow per share (Unadj.) Rs15.444.3 34.6%  
Dividends per share (Unadj.) Rs2.002.00 100.0%  
Dividend yield (eoy) %0.30.3 85.9%  
Book value per share (Unadj.) Rs380.0198.6 191.3%  
Shares outstanding (eoy) m3.90282.17 1.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.01.7 58.9%   
Avg P/E ratio x60.718.2 333.1%  
P/CF ratio (eoy) x45.313.5 336.2%  
Price / Book Value ratio x1.83.0 60.9%  
Dividend payout %17.46.1 286.0%   
Avg Mkt Cap Rs m2,714168,625 1.6%   
No. of employees `0000.412.0 3.7%   
Total wages/salary Rs m50520,561 2.5%   
Avg. sales/employee Rs Th6,073.08,196.0 74.1%   
Avg. wages/employee Rs Th1,137.41,708.1 66.6%   
Avg. net profit/employee Rs Th100.7768.5 13.1%   
INCOME DATA
Net Sales Rs m2,69698,655 2.7%  
Other income Rs m1252,081 6.0%   
Total revenues Rs m2,822100,736 2.8%   
Gross profit Rs m-4615,858 -0.3%  
Depreciation Rs m153,259 0.5%   
Interest Rs m103,346 0.3%   
Profit before tax Rs m5411,335 0.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m01,672 0.0%   
Tax Rs m103,756 0.3%   
Profit after tax Rs m459,250 0.5%  
Gross profit margin %-1.716.1 -10.7%  
Effective tax rate %17.733.1 53.3%   
Net profit margin %1.79.4 17.7%  
BALANCE SHEET DATA
Current assets Rs m1,73866,968 2.6%   
Current liabilities Rs m54540,211 1.4%   
Net working cap to sales %44.327.1 163.2%  
Current ratio x3.21.7 191.6%  
Inventory Days Days4883 58.2%  
Debtors Days Days481 5.3%  
Net fixed assets Rs m1233,322 0.0%   
Share capital Rs m39282 13.8%   
"Free" reserves Rs m1,44355,770 2.6%   
Net worth Rs m1,48256,052 2.6%   
Long term debt Rs m035,738 0.0%   
Total assets Rs m2,077132,888 1.6%  
Interest coverage x6.74.4 153.1%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x1.30.7 174.9%   
Return on assets %2.69.5 27.5%  
Return on equity %3.016.5 18.3%  
Return on capital %4.317.8 24.2%  
Exports to sales %00-   
Imports to sales %24.50-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m659NA-   
Fx inflow Rs m1762,998 0.0%   
Fx outflow Rs m67322,859 2.9%   
Net fx Rs m-65640,140 -1.6%   
CASH FLOW
From Operations Rs m9013,242 0.7%  
From Investments Rs m105-6,990 -1.5%  
From Financial Activity Rs m-14-7,387 0.2%  
Net Cashflow Rs m181-2,971 -6.1%  

Share Holding

Indian Promoters % 0.0 48.3 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 3.8 6.9 55.1%  
FIIs % 0.1 34.4 0.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.2 10.5 201.9%  
Shareholders   4,783 56,727 8.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FULFORD INDIA With:   UNICHEM LAB  AUROBINDO PHARMA  IPCA LABS  CADILA HEALTHCARE  SUN PHARMA  

Compare FULFORD INDIA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Economic Growth and Stock Markets: It's Not All Gloom and Doom(Podcast)

In addition to the usual stock market updates of the week, I talk about how RBI's monetary policy decision and slowing economy impacts you and your portfolio of stocks.

Related Views on News

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, GLENMARK PHARMA has posted a net profit of Rs 1 bn (up 11.1% YoY). Sales on the other hand came in at Rs 26 bn (up 15.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

More Views on News

Most Popular

Could this Smallcap Be the Next Page Industries?(Profit Hunter)

Nov 27, 2019

A single stock - Coca Cola, made Buffett billions. Here's your chance to break into the crorepati club with a single smallcap stock investment.

How We Made 12.68% in One Overnight Trade(The 5 Minute Wrapup)

Nov 25, 2019

This one trade had my subscribers laughing all the way to the bank.

Growth Stocks or Value Stocks... What Will Make You More Money in this Bull Market?(Profit Hunter)

Nov 28, 2019

Should you invest in growth stocks or value stocks to make strong returns in this market?

Two Trends to Look at as Sensex Crosses 41,000 Levels(Views On News)

Nov 26, 2019

The two trends that are playing out as Sensex touches new record high.

The Best Trading Strategy for Fast Profits

Nov 29, 2019

Vijay and I have decided to team up and bring you a unique offering never seen before in the Indian stock markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

FULFORD INDIA SHARE PRICE


Jul 30, 2015 (Close)

TRACK FULFORD INDIA

  • Track your investment in FULFORD INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

FULFORD INDIA 8-QTR ANALYSIS

COMPARE FULFORD INDIA WITH

MARKET STATS